chartexchange

CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia

GlobeNewswire Inc. | Nov 16, 2026 4:02 PM EST

24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage 

Read original article